Pharmaceutical Executive
January 26, 2018
Features
38
1
In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.
January 12, 2018
Features
38
1
Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.
January 11, 2018
Columns
38
1
States will continue to press for price controls, while FDA will tackle opioids and promote innovation.
January 09, 2018
From the Editor
38
1
The advent of immunocellular therapies marks a major milestone in pharma, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance,
January 09, 2018
Columns
38
1
Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
January 08, 2018
Columns
38
1
Program puts a new-and very real-spin on patient nutrition.
January 01, 2018
Columns
38
1
Is getting more clarity on Brexit ramifications for pharma and European public health really at the top of new-year to-do lists?
January 01, 2018
Special Sponsored Section
38
1
Three pivotal developments that occurred in 2017 illustrate the growing relevance and influence of the Swiss pharmaceutical and life sciences industry on the world stage. Companies in Switzerland are also playing innovative roles in reshaping the pharma value chain and contemporary paradigm of healthcare provision.
January 01, 2018
Issue PDF
38
1
Click the title above to open the Pharmaceutical Executive January 2018 issue in an interactive PDF format.